Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study

( views:90, downloads:0 )
Author:
HAN Ding-fen()
ZHOU Xin()
HU Ming-bai()
XIE Wei()
MAO Zong-fu()
CHEN Dong-e()
LIU Fang()
ZHENG Fang()
Journal Title:
CHINESE MEDICAL JOURNAL
Issue:
Volume 118, Issue 18, 2005
DOI:
Key Word:
estrogen;metabolizing genes;polymorphism;breast neoplasms;risk factor

Abstract´╝Ü Background Endogenous estrogen plays a very important role in the carcinogenesis and progression of breast cancer. The enzymes involved in the biosynthesis and metabolism of estrogen have been proposed to contribute to this effect. To examine this hypothesis, we conducted a case-control study to investigate the relationship between polymorphisms of genes responsible for estrogen biosynthesis (CYP17, cytochrome P450c17a and CYP19, aromatase cytochrome P450) and estrogen sulfation of inactivation (SULT1A1, sulfotransferase1A1) and the risk of breast cancer in Chinese women. Methods This study involved 213 breast cancer patients and 430 matched controls. PCR-based restriction fragment length polymorphism (RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the mononucleotide transition of CYP17 and SULT1A1 and tandem repeat polymorphism of CYP19. Logistic regression analyses were used to determine OR and 95% CI of each and all three high-risk genotypes, of all three genotypes combined, and of estrogen exposure factors. The relationship between each high-risk genotype and clinicalpathological characteristics were also assessed. Results The frequency of A2 allele of CYP17 was 49.8% in cases and 49.1% in controls (P=0.82). The frequency of His allele of SULT1A1 was significantly higher in cases (13.6%) than in controls (9.5%) (P<0.05). There was also significant difference of the (TTTA)10 allele of CYP19 which was 12.4% in cases and 8.2% in controls (P<0.05). When the CYP17 A2 allele, CYP19 (TTTA)10 and SULT1A1 His allele were considered as the "putative high-risk" genotype, there was an increased risk of breast cancer with the number of high-risk genotypes in a dose-response effect (trend, P=0.05). In multivariate analysis, the SULT1A1 genotype remained the most significant determinant for breast cancer, with OR=2.37 (95% CI 1.23-4.74), followed by CYP19, with OR=1.75 (95% CI 1.27-3.56). The (TTTA)10 allele of CYP19 was associated with tumor size, and the His allele of SULT1A1 associated with status of lymph node metastasis. Conclusions This study supports the hypothesis that breast cancer can be initiated by estrogen exposure and that estrogen metabolizing genes are involved in this mechanism. This multigenic model is useful for identifying individuals who are at higher risks of breast cancer.

  • [1]Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
  • [2]Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-242.
  • [3]Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
  • [4]Henderson BE, Bernstein L. The international variation in breast cancer rates: an epidemiological assessment. Breast Cancer Res Treat 1991;18:s11-s17.
  • [5]Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-232.
  • [6]Santen RJ, Song RX, Zhang Z, et al. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocr Relat Cancer 2003;10:111-130.
  • [7]Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17.Hum Mol Genet 1994;3:1873-1876.
  • [8]Haiman CA, Hankinson SE, Spiegelman D, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.Cancer Res 1999;59:1015-1020.
  • [9]Feigelson HS, Coetzee GA, Kolonel LN, et al. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1997;57:1063-1065.
  • [10]Feigelson HS, McKean-Cowdin R, Coetzee GA, et al. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates.Cancer Res 2001;61:785-789.
  • [11]Huang CS, Chern HD, Chang KJ, et al. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.Cancer Res 1999;59:4870-4875.
  • [12]Miyoshi Y, Iwao K, Ikeda N, et al. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000;36:2375-2379.
  • [13]Siegelmann-Danieli N, Buetow KH. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 1999;79:456-463.
  • [14]Polymeropoulos MH, Xiao H, Rath DS, et al. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res 1991;19:195.
  • [15]Kristensen VN, Andersen TI, Lindblom A, et al. A rare CYP19 (aromatase) variant 05-increase the risk of breast cancer. Pharmacogenetics 1998;8:43-48.
  • [16]Haiman CA, Hankinson SE, Spiegelman D, et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 2000;87:204-210.
  • [17]Miyoshi Y, Iwao K, Ikeda N, et al. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer 2000;89:325-328.
  • [18]Weinshilboum RM, Otterness DM, Aksoy IA, et al. Sulfation and sulfotransferases 1: sulfotransferase molecular biology: cDNAs and genes. FASEB J 1997;11:3-14.
  • [19]Coughtrie MW, Gilissen RA, Shek B, et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 1999;337:45-49.
  • [20]Raftogianis RB, Wood TC, Otterness DM, et al. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997;239:298-304.
  • [21]Nowell S, Sweeney C, Winters M, et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002;94:1635-1640.
  • [22]Zheng W, Xie D, Cerhan JR, et al. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:89-94.
  • [23]Seth P, Lunetta KL, Bell DW, et al. Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res 2000;60:6859-6863.
  • [25]Wu AH, Seow A, Arakawa K, et al. HSD17B1 and CYP17 polymorphisms and breast cancer risk among chinese women in Singapore. Int J Cancer 2003;104:450-457.
  • [26]Baxter SW, Choong DY, Eccles DM, et al. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001;22:347-349.
  • [27]Kristensen VN, Harada N, Yoshimura N, et al. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 2000;19:1329-1333.
  • [28]Adjei AA, Weinshilboum RM. Catecholestrogen sulfation: possible role in carcinogenesis.Biochem Biophys Res Commun 2002;292:402-408.
  • [29]Raftogianis R, Creveling C, Weinshilboum R, et al. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 2000;27:113-124.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn